Switzerland's Medacta H1 revenue rises 9.7% in constant currency
Switzerland's Medacta H1 revenue rises 9.7% in constant currency
Overview
Swiss medical device maker's preliminary H1 revenue rose 9.7% in constant currency
Growth driven by innovations, new surgeon recruitment, and expanded medical education
Company confirmed FY 2026 and mid-term outlook
Outlook
Medacta targets 2026 revenue growth of 10% to 14% in constant currency
Company expects 2026 adjusted EBITDA margin to expand by around 50bps vs prior year (27.9%)
Medacta sees mid-term (2024–2027E) revenue CAGR of 12% to 15% in constant currency
Result Drivers
INNOVATION AND NEW PRODUCTS - Growth attributed to differentiating innovations, including the AMIS platform for Hip, NextAR AR navigation systems, and new products in Knee and Extremities
NEW SURGEON RECRUITMENT - Increased volumes from new surgeons attracted through expanded sales force and medical education initiatives
US SALES CHANNEL TRANSITION - Slower US growth in Spine due to ongoing transition to direct sales and Medacta-focused agents, with partial offset from new customer revenues
Company press release: ID:nEQ4xzN24a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Revenue |
| EUR 368 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Medacta Group SA is CHF170.50, about 25.9% above its July 30 closing price of CHF135.40
The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 30 three months ago
Reuters Recommended Reads
July 30 - Stryker beats quarterly estimates on strong demand for medical devices
July 29 - GE Healthcare Q2 revenue rises 5.7% on Pharmaceutical Diagnostics unit strength
July 29 - Bausch + Lomb Q2 revenue beats on surgical segment growth; lifts outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Medacta SA
See all newsBrief: Medacta Group Updates 2026 Guidance, Reiterates 2024-2027 Mid-Term Outlook
Swiss medical device maker Medacta H1 revenue rises on Asia Pacific, EMEA strength
Brief: Medacta H1 Adjusted EBITDA EUR 97 Million
Switzerland's Medacta H1 revenue rises 9.7% in constant currency
Brief: Medacta H1 Revenue EUR 368 Million